▎Edited by the WuXi AppTec content team

Source of the image: Screenshot from the CDE official website

Targeting chemokine receptor 8 (CCR8) is considered a promising cancer treatment approach, whichRepresentsSelective Depletion of Tumor InfiltrationTregsUnique Target。

Studies have shown that,Tregs willInhibition of Tumor MicroenvironmentCD8+ T cells in , and thenPromote tumor progression, andHindered immune checkpoint inhibitorsEffectiveness.Depletion of systemic Tregs can enhance anti-tumor immunity, but it may also trigger adverse autoimmune reactions.Therefore,Need to selectively target the tumor microenvironmentTregs、Without affectingPeripheralTregsTherapeutic drugs.CCR8 is mainly expressed in the tumor microenvironment.in ChinaTregs CellsAbove, it represents such a promising anti-cancer target.

BAY 3375968 is an antibody therapy. According to preclinical study results published at the 2022 American Association for Cancer Research (AACR) Annual Meeting, the productCan be located withTregsSurface CCR8Protein binding,Leading to a reduction in regulatory T cells and further suppressing their immunosuppressive activity, enhancing the immune response against cancer.Animal experiments have shown that the product can enhance the anti-cancer effect of immunotherapy when used in combination with PD-1/PD-L1 inhibitors.

According toClinicalTrialsAccording to the official website, Bayer is currently conducting a Phase 1 first-in-human clinical study to evaluate the safety of BAY 3375968 when used alone or in combination with the PD-1 inhibitor pembrolizumab, and to explore the optimal dosage of this product in patients with advanced solid tumors.

Public data shows that more than a dozen CCR8-targeted products are currently undergoing clinical research worldwide.Products that have progressed more rapidly have entered the Phase 2 clinical research stage.Most of these drug types are monoclonal antibody products, such as those under research by Zai Lab.ZL-1218, BGB-A3055 under research by BeiGene, ICP-B05 (CM369) co-developed by InnoCare Pharma and Connaught Biologics, etc.; the rest also include small molecule drugs, such as the small molecule antagonist targeting CCR8 being developed by Amephi Pharmaceuticals.IPG7236。

Reference MaterialsMaterial:

[1]Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. Retrieved July 23，2024, From https://www.cde.org.cn/main/xxgk/listpage/da6efd086c099b7fc949121166f0130c

[2]Abstract 2866: BAY 3375968: An afucosylated anti-CCR8 antibody depleting activated intratumoral regulatory T cells as a cancer immunotherapy. Retrieved June 15, 2022, from https://aacrjournals.org/cancerres/article/82/12_Supplement/2866/704369/Abstract-2866-BAY-3375968-An-afucosylated-anti

[3] Bayer R&D Pipeline.Retrieved Apr 30，2024, From https://www.bayer.com/sites/default/files/ph-rd-pipeline-2024-05-final-1.pdf